Category: <span>Tecentriq</span>

Category: Tecentriq

Atezolizumab, bladder cancer drug for mesothelioma, immunotherapy for mesothelioma, keytruda for mesothelioma, Mesothelioma News, opdivo for mesothelioma, Tecentriq

Tecentriq Raises Hope of New Mesothelioma Clinical Trial

 

The FDA recently approved immunotherapy drug Tecentriq (atezolizumab) for certain bladder and non-small cell lung cancers, raising hopes for a mesothelioma-specific clinical trial in 2017. Tecentriq, a product of Genentech Oncology, is following the path of Keytruda (pembrolizumab) and Opdivo (nivolumab) as drugs that target a specific protein blocking a body’s immune system from attacking…

The post Tecentriq Raises Hope of New Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.